



BEST AVAILABLE COPY




GB04/4552



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport

South Wales
NP10 8QQ




**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

He Behen

Dated

3 November 2004

Patents Form 1/77

Patents Act 1977
(Rule 16)

**The
Patent
Office**

29MAY04 E899911-4 D00056
P01/7700 0.00-0412070.5 CHEQUE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference **P33710GB/AA**

2. Patent application number
(The Patent Office will fill in this part)

0412070.5

28 MAY 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)

**Eumedic Limited
3 Charnham Lane
Hungerford
Berkshire RG17 0EY**

Patents ADP number (If you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UK

AL4M02.7.00.8878241 001

4. Title of the invention

Treatment Device

5. Name of your agent (If you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

**Kilburn & Strode
20 Red Lion Street
London
WC1R 4PJ**

Patents ADP number (If you know it)

125001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

Patents Form 1/77


9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 33

Claim(s) 5

Abstract 0

Drawing(s) 20 + 20 

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 2

Request for preliminary examination and search (Patents Form 9/77) 1


Request for substantive examination (Patents Form 10/77) 0

Any other documents (please specify) 0

11.

I/We request the grant of a patent on the basis of this application.

Signature



Date

28/5/94

12. Name and daytime telephone number of person to contact in the United Kingdom

Tel: 020 7539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

TREATMENT APPARATUS FOR APPLYING ELECTRICAL IMPULSES
TO THE BODY OF A PATIENT

5 This invention relates to treatment apparatus for applying electrical impulses to a living body through the skin for treating a variety of clinical conditions.

10 In particular, in its preferred form at least, the invention relates to a handheld treatment device, and to a treatment apparatus and treatment system including such a device, in which the device makes physical contact with the skin and a repeatedly generated AC waveform is supplied to the electrodes for application at the surface of the skin and for monitoring changes in the skin impedance.

15 It is known to treat animals and humans by the use of electrostimulation. However, such treatment apparatus is generally cumbersome and expensive to manufacture and run, and usually only has application in certain specific clinical conditions. Furthermore, treatment is often costly and success rates may be low.

20 It is also known to employ handheld scanning devices using electrostimulation for assistance in the development of treatments for animals and humans. However, these devices again tend to be limited in their application.

25 There is therefore a need for more inexpensive, portable equipment that is both flexible and easy to use and that is capable of treating a wide variety of clinical conditions.

The present invention seeks to provide a new treatment device, which is effective and easy to use and which has a wide range of clinical applications.

In its preferred form at least, the invention also seeks to provide a handheld device for the treatment of a wide variety of clinical indications.

5 Another aim of the present invention is to provide a treatment method, device and apparatus, which are non-invasive and which demonstrate benefits in the treatment of a variety of clinical conditions with few harmful side effects.

10 In brief, the present invention concerns a treatment device, apparatus, system and method for applying electrical impulses of relatively high amplitude and short duration to the body of an animal or patient through the skin for stimulating repair processes within the body.

15 The invention, at least in its preferred form described below, depends on using alternating current electrostimulation via a biofeedback system based on reaction to skin impedance. The impulses from the device are preferably of short duration ($10\mu\text{s}$ approx) and of relatively high amplitude (80v). The influence is critically guided by careful observation using specific measured parameters of the impulses depicted on the device screen. Due to the short duration of impulse the energy of the signal is extremely small and harmful effects highly unlikely.

25 The equipment is able to detect the zones of lowest skin impedance in an 'area of possibility' (for example between two concentric rectangular electrodes) and to denote these by numerical readout. Dialogue is initiated through the low resistance points of the skin and guided by observation of this dialogue by a trained practitioner.

Via afferent nerve endings the impulses from the device enter the central nervous system (CNS) at the anterior horns of the spinal cord. Both myelinated

and unmyelinated nerves are stimulated by the impulses. By numerical supremacy the majority of the dialogue takes place via the c-fibres. Impulses are conducted up the dorsal and ventral spinothalamic tracts, the dorsal and ventral spino cerebellar tracts and the spino tectal tracts. There is a
 5 contribution via the reticulo-cerebellar fibres and the pontine tegmentum.

Some of the facilitatory effects of the electrostimulatory system are believed to be mediated by this part of the reticular formation. Continuation of the reticular formation communications beyond the brain stem to the cortex with associated influence on cortical responses is also anticipated. Efferent signals
 10 descend via the corticospinal tracts. Frequently, more than one segmental level is influenced simultaneously.

Electrostimulatory influences have small local effects in the form of polarisation of molecules and local vasomotor effects; with some possible
 15 influence on the graded potentials locally. Mediation of local influences is via neuropeptide release.

The majority of the beneficial influence is via efferent nerves from the CNS. At a segmental level, there is also sometimes influence on pain pathways via
 20 the saturation of transmitter at the site of entry into the lateral spinothalamic tract, particularly if there is marked A fibre involvement.

Electrostimulation signals act on both local reflex arcs (also influencing the sympathetic chain) with their concomitant effects on internal organ, vessels and
 25 muscles; as well as entering the CNS via the ascending tracts for higher connections which will lead to general neuropeptide release (with resultant effect on general homoeostasis), endocrine release, parasympathetic influence and efferent signals down the corticospinal tracts to the relevant levels. Processes of disease control and pain with this form of electrostimulation are

mainly mediated via the descending impulses in the CNS to an appropriate level for subsequent peripheral 'local' neuropeptide release. Further mediation is influenced through the autonomic nervous system both via local effects and general physiology.

5

Thus, according to a first aspect of the present invention there is provided a handheld treatment device for applying electrical impulses to a living body through the skin, for treating a variety of clinical conditions, comprising: a pair of electrodes for contact with the skin; a waveform generator for repeatedly
10 generating an AC waveform for applying electrical impulses through the electrodes to the skin; a detector for detecting changes in the skin impedance and for generating output signals representing the skin impedance; means responsive to the output signals from the detector for monitoring the responsivity of the skin; and indicator means for generating a first indication
15 when a predetermined level of responsivity is reached and a second indication when a pre-determined treatment has been administered.

In a preferred embodiment, the skin impedance alterations, which occur as a result of both the local and general state, are depicted numerically on a screen
20 of the treatment device and influence the next outgoing signal from the device. Moreover, several other aspects of the signal exchange between the skin and the treatment device may be depicted numerically on the screen (amplitude, rate, gradient, speed and so on). Some of these numbers use mathematical algorithms to be able to generate the best possible use of the electrostimulatory
25 dialogue. The numerical representations may then be used by the practitioner to guide the treatment processes, via a number of protocols. The intention is to guide the locked or disturbed CNS foci into a restorative state, thereby initiating or re-stimulating normal repair processes, both centrally and locally. Due to the strong CNS (vs.local) component of the process of exchange, 'old'

foci from previous pathological states can be influenced simultaneously, leading also to unexpected resolutions of past disease states.

5 In its preferred form, the treatment device is a handheld battery powered device.

Advantageously, the detection means generates output signals in the form of pulses whose duration represents the skin impedance; the monitoring means measures the duration t of each pulse; and the indicating means is arranged to
10 generate each indication when t satisfies a predetermined function of t .

Preferably, the indicating means is arranged to generate the first indication when $t_2 = 4.087 t_1^{0.7131}$ and to generate the second indication when $dZ/dt = 0$.

15 Conveniently, the electrical impulses generated by the handheld device are of high initial amplitude and brief duration. The resulting treatment is non-invasive and is believed to generate few harmful side effects. The device has been found during trial to be extremely effective in treating a wide variety of clinical indications.

20 The handheld device according to the invention has a number of advantages, including its ease of use and versatility, as well as the fact that the treatment cost is low while the efficacy promises to be relatively high.

25 According to another aspect of the present invention, there is provided treatment apparatus for applying electrical impulses to a living body through the skin, for treating a variety of clinical conditions, comprising: a pair of electrodes for contact with the skin; a waveform generator for repeatedly generating an AC waveform for applying electrical impulses through the
30 electrodes to the skin; means responsive to a resistance generated between the

electrodes due to the skin impedance for detecting the responsivity of different zones of a pre-determined area of the body and for producing output data representing the responsivity of each zone; a store for the output data; and means for selecting a treatment zone from amongst the different zones based on an evaluation of the output data to select the zone of greatest responsivity.

Preferably, the output data from the detecting means is in the form of numerical values, and the selecting means evaluates the output data on the basis of the highest values.

10

In the preferred embodiment described below, the selecting means comprises means for processing the output data contained in the store, and a display operable by the processing means for indicating the selected treatment zone. For example, the display may be arranged to display a body map of the pre-determined treatment area with the respective output data being displayed at a plurality of map locations representing the corresponding zones of the pre-determined area.

15

According to a further aspect of the present invention, there is provided a treatment system for the treatment of a living body, comprising: a treatment device for applying electrical impulses to the body through the skin, the treatment device including a CPU; a PC for storing patient records; a cradle for the treatment device, the cradle being connected to or incorporated as a part of the PC; and means for receiving a smart card including a unique patient ID and for providing access to the patient records associated with the unique patient ID.

20

25

Advantageously, the smart card may be arranged to carry a PIN number as well as the unique patient ID, and the system may include input means by which a

patient may be requested to supply their PIN number. When a match occurs between the input PIN number and the PIN number or the unique patient ID on the smart card, then the system is arranged to enable access between the treatment device and the practitioner's PC.

5

A further aspect of the invention features a method of treating of a human or animal through the skin by means of the present treatment device.

According to this aspect of the invention, there is provided a method of treating a living body through the skin, comprising the steps of: placing a pair of electrodes in contact with the skin; generating an AC waveform to supply electrical impulses through the electrodes to the skin; detecting changes in the skin impedance and generating output signals representing the skin impedance; monitoring the responsivity of the skin; and indicating firstly when a predetermined level of responsivity is reached and secondly when a predetermined treatment has been administered.

10
15

The invention is described further, by way of example, with reference to the accompanying drawings, in which:

20

Figure 1 is a perspective view of a handheld treatment device according to the present invention;

Figure 2 is a diagram representing the nervous system within the human body;

25

Figure 3 is a diagram representing the transmission of information from the central nervous system of the body to the cells of body organs;

Figure 4 is a diagram demonstrating use of the treatment device of Figure 1;

Figure 5 is an elaboration of Figure 4;

Figure 6 is a diagram of the electrodes of the treatment device of Figure 1;

Figure 7 is a block diagram of the circuitry within the treatment device of Figure 1;

5 Figure 8 is a waveform diagram showing an output of a waveform generator in the circuit of Figure 7;

Figure 9 is a waveform diagram showing a detail of the output of Figure 8;

10 Figure 10 is a waveform diagram showing the signal generated at one point of the circuit of Figure 6 when the device is not in use but a load is connected across the electrodes to simulate skin contact;

Figure 11 is a signal diagram showing the signals generated at various points of the circuit of Figure 7 when the treatment device is in use;

15 Figure 12 is a waveform diagram showing how the signal at the electrodes of the treatment device varies in use as skin impedance changes;

Figure 13 is a waveform diagram corresponding to that of Figure 12 and showing the waveform at the electrodes at three different time intervals;

Figure 14 is a graph representing the changes of skin impedance with time;

20 Figures 15 and 16 are representations of body treatment maps, which are developed during treatment and displayed on a display of the treatment device;

Figures 17 to 20 are flow charts representing software processing by a CPU of the treatment device shown in Figure 7;

25 Figure 21 is a block diagram of a treatment system incorporating the treatment device of Figures 1 to 20;

Figures 22 and 23 are data flow diagrams representing use of the treatment system of Figure 21; and

Figure 24 is a flowchart representing software processing by the CPU of the treatment device in the application of the device in the treatment system of Figure 21.

5 Referring initially to Figures 1 to 5, the present invention comprises a handheld treatment device 10 for applying electrical impulses to a human or animal body through the skin. For the purposes of the present description, the treatment of a human being will be described. The treatment device 10 is illustrated in Figure 1 and is designed to be placed in contact with the skin and to generate short AC
10 electrical impulses for application to the skin by way of electrodes (described below).

Referring now to Figure 2, the body's maintenance system is derived from the embryological layer known as the neuro-ectoderm. The skin, the nervous
15 system of the body and the spinal cord are all derived from this embryological layer and consequently are all in mutual communication. Figure 2 shows how a network of nerve fibres 12 connect the skin 14 to various organs 16 of the body and to the spinal cord 18 with its central nervous system and its connection to the brain 20. Information from the control centre 22 of the
20 central nervous system controls the release of specific neuro peptides 24 at the nerve endings, which in turn controls the replacement, structure and behaviour of cells 26 within the body organs 16 as indicated in Figure 3. The network 12 of nerve fibres also controls the transmission of information between the skin 14 and the central nervous system, and abnormalities in the body are reflected
25 via this network 12 in changes in the impedance of the skin 14.

Figures 4 and 5 indicate how the application of the AC electrical impulses from the treatment device 10 at carefully selected locations of the skin 14 may transmit information via a communication pathway 28 through the nerve

network 12 to the control centre 22 of the central nervous system and stimulate this control centre into triggering neuro peptide release for activating repair processes in the organs 16. Changes in skin impedance ensue and can be detected by the treatment device 10. Thus, a dialogue between the device 10 and the control centre 22 of the central nervous system, via the skin 14 and the nerve network 12, is initiated and can be employed to trigger repair and to monitor the treatment process and its effects. The treatment is non-invasive and only very small amounts of energy are applied to the body and hence harmful effects are highly unlikely.

The device itself will now be described further with reference to Figures 1, 6 and 7.

The treatment device 10 comprises a body 30 having a pair of electrodes 32 at one end and having on its back an on or off switch 34, a display 36 and a series of user control buttons 38. Four such buttons are shown in Figure 1, but there may be any number depending on the number of different functions that may be controlled by the user.

The electrodes 32 have a very specific form designed primarily to ensure skin contact whether the skin is bare or is covered by hair or fur. More particularly, the electrodes are designed as a series of five parallel combs, in which the two outermost combs 32a constitute one electrode; the central comb 32b constitutes the other electrode, and the remaining two combs 32c flanking the central comb 32b are insulating elements. The electrodes 32a and 32b are therefore formed from a conductive material, while the combs 32c are formed from an insulating material. The dimensions of the combs are, however, identical, and each comb comprises a series of teeth arranged approximately 2.5 mm apart and having a length of approximately 2 mm.

The electrical circuitry within the treatment device 10 is shown in Figure 7 and is controlled by the on/off switch 34 and powered by a battery 40 for applying AC electrical impulses to the electrodes 32.

5

As shown, a central processing unit (CPU) 42 including a clock 44 is arranged to generate an output at point A of Figure 7 in the form of a train of rectangular pulses. Such pulses are supplied to a waveform generator 46 for triggering an output from the generator at point B of the circuit. The output of the waveform generator 46 is an AC decaying oscillation, which is repeatedly triggered by the pulses from the CPU 42 and which is applied to one of the electrodes 32. A voltage signal is generated across the electrodes 32, effectively at point C in Figure 7, whose magnitude is dependent on whether the electrodes are in open circuit or whether they are in contact with the skin and are responsive to the skin impedance (represented as a resistor 48). This voltage signal is applied to a comparator 50, where it is compared with a threshold voltage output by the CPU 42. The comparator 50 generates a pulse output at point D of the circuit, in which the rising edge of each pulse corresponds with the voltage from the electrodes 32 increasing above the threshold level and the trailing edge of each pulse corresponds with the voltage from the electrodes 32 falling below the threshold level. A counter 52 within the CPU 42 also connected to the clock 44 counts the clock signal for the duration of each such pulse and thereby produces a numerical value representing the pulse duration. These numerical values are transmitted by way of a memory bus 54 to a memory or store 56.

25

The user control keys 38 can be employed for providing inputs to the CPU 42 to cause the CPU 42 to adjust the frequency, duration, and amplitude of the pulses supplied to the waveform generator 46 and to determine whether these pulses are supplied at regular intervals, or repeatedly in clusters. The

waveform generator 46 is arranged to respond accordingly for supplying a corresponding AC waveform to the electrodes 32, and in this way the electrical impulses applied to the skin can be adjusted and treatment can be controlled. The CPU 42 processes the information obtained during a treatment session and displays the results on the display 36 as well as storing them in the memory 56. The CPU 42 is also arranged to activate one or more audio indicators 58 for signalling certain events in the treatment session.

In addition, a series connection of a switch 60 and a load 62 is connected across the two electrodes 32 and may be switched into the circuit in response to a user generated output from the CPU 42, either in order to simulate skin contact when the electrodes 32 are not in contact with the skin of a patient or to provide a filter in cases of high skin sensitivity.

The signals at the various points of the circuit of Figure 7 and in various circumstances are shown in Figures 8 to 13.

Figure 8 shows the rectangular pulse signal output by the CPU 42 and generated at the point A of the circuit, together with the corresponding repeated AC waveform output by the waveform generator 46 at point B of the circuit. A single cycle of the AC waveform at point B is shown in Figure 9, and has an initial amplitude V_{peak} , a half wavelength t_1 and a decay t_{decay} . The amplitude V_{peak} is dependent on the pulse width of the pulse signal at point A, which can be set by one of the control keys 38 according to a strength setting in a range from 1 to 250. In the example shown in Figure 9, the strength setting is set to 20 and V_{peak} is 230 volts. t_1 in this example is 40 microseconds and t_{decay} , to the point where the voltage has decayed to about 10% of V_{peak} , is 1.15 milliseconds.

The repetition rate of the AC waveform output by the waveform generator 46,
 as shown in Figure 8, is determined by and corresponds with the frequency of
 the pulse signal at the point A and is set by the user from one of the control
 keys 38. The repetition rate is preferably adjustable from 50 Hz to 351 Hz. A
 5 further one of the control keys 38 sets whether the pulses output by the CPU 42
 at the point A are generated at regular intervals or in clusters according to the
 intensity of the treatment required. The intensity of treatment can be set in a
 range from 1 to 8, representing the number of pulses, i.e. from 1 to 8, in each
 cluster. An intensity of 1 thus represents a series of pulses occurring at regular
 10 intervals, while an intensity of 8 represents clusters of 8 pulses at a time. The
 spacing between the individual pulses, or clusters of pulses, at the point A
 corresponds to the overall cycle time t_{repeat} of each individual AC waveform, or
 cluster of waveforms, in the repeated cycle generated at the point B of the
 circuit and is also controlled by one of the user keys 38. This pulse spacing is
 15 defined as the gap in treatment applications, and the gap can be adjusted within
 the range from 10 to 80 corresponding to a spacing t_{repeat} in a range from 220
 microseconds to 1,600 microseconds.

By switching the load 62 into the circuit, the AC waveform output by the
 20 waveform generator 46 at the point B generates a waveform across the load 62
 at the point E in Figure 7. The waveform at the point E is a modification of the
 signal at the point B, in which the half wavelength t_1 is extended, and is shown
 in Figure 10.

25 The signals described thus far effectively represent a situation where the
 treatment device 10 is not in contact with the skin and where the device
 remains unaffected by skin impedance. The signals arising in use of the device
 are shown in Figure 11, which represents the events triggered by one pulse
 from the pulse signal at the point A and hence one full cycle of the AC

waveform at the point B. As shown, the effect of the skin impedance results in a signal generated at the point C of Figure 7, which is an AC waveform having an extended half wavelength t_1 and a fewer number of voltage peaks by comparison with the AC waveform at the point B. This signal at the point C is supplied to the comparator 50 where it is compared with a threshold voltage V_{th} . On each occasion that the signal at the point C increases above the threshold voltage the comparator 50 triggers the leading edge of a new pulse, and on each occasion that the signal at the point C falls below the threshold V_{th} the comparator generates the trailing edge of a pulse. The pulse output of the comparator 50 at the point D of Figure 7 is shown in Figure 11.

It has been found that, as treatment continues, the skin impedance falls and consequently the signal at the point C becomes increasingly extended. This is illustrated in Figure 12 where an initial response signal at the point C is represented by the line V_1 having a half wavelength t_1 , and a subsequent response signal at the point C is represented by the line V_2 having a half wavelength t_2 . It is evident that t_1 is less than t_2 . Eventually, the response signal at the point C will have a half wavelength t_0 , in which the threshold voltage is not exceeded at all.

This situation is represented in Figure 13, which shows how the signal at the point C adapts as a treatment application progresses. Here, the initial skin impedance on first application of the AC waveform output by the waveform generator 46 at the point B is represented by the first signal in Figure 13 and the half wavelength t_1 ; a subsequent application of the AC waveform at the point B is represented by the second signal in Figure 13 and a half wavelength t_2 ; and a later application of the AC waveform at the point B is represented by the third signal and a half wavelength t_0 .

The graph in Figure 14 represents the change of skin impedance with time for one specific zone only of a given area of the body. By monitoring this change, the CPU 42 can deduce how the patient is responding to the application of the electrical impulses. The time that it takes to reach the point X on the graph represents the responsivity of the skin of this particular body zone. Point X has been selected empirically to be the point which satisfies the following equation:

$$t_2 = 4.087 t_1^{0.7131}$$

The point Y on the graph represents the point at which the rate of change of skin impedance Z with time t is zero, i.e.:

$$dZ/dt = 0$$

At the point Y, a standard treatment may be considered to have been administered. Referring back to Figure 13, the second signal having the half wavelength t_2 corresponds to the point X in Figure 14, and the third signal having the half wavelength t_0 corresponds to the point Y on the graph in Figure 14.

In order to obtain a measurement corresponding to skin impedance, ideally the peak voltage values of each of the signals in Figure 13 would be measured. However, it has been found more practical to measure the duration t of each initial half wave, and for this purpose the comparator 50 generates pulses in response to the crossings of the threshold voltage V_{th} and the counter 52 counts to a numerical value determined in each instance by the generation of each pulse in the signal at the point D. These numerical count values are displayed on the display 36 of the device 10 under the control of the CPU 42.

Referring to Figure 1, the initial reading for the count value corresponding to the half wavelength t_1 for the first signal in Figure 13 occurring at the start of a treatment application is shown at the display location 36a at the top left hand corner of the display 36; the continually varying count value representing the half wavelength t as it changes during a treatment application is shown in the display location 36b in the lower left hand corner of the display 36, and a further count value representing the change of skin impedance with time, i.e. dZ/dt , and derived from counting the rate at which t changes by means of the counter 52 is displayed at the display location 36c on the display 36. At the moment when the point X is reached on the graph in Figure 14, the CPU 42 is arranged to trigger the audio indicator 58 to ring a bell. At the same time, the CPU 42 stops the counter 52 and the count value at the display location 36b is fixed and is stored in the memory 56. At the moment at which the point Y on the graph in Figure 14 is reached, as represented by the value at the display location 36c showing zero, the CPU 42 is arranged firstly to trigger the audio indicator 58 to sound a buzzer.

The most basic operation of the handheld treatment device 10 will now be described.

20

Firstly, the physician switches the device on by means of the on/off switch 34 and sets the desired treatment strength and repetition rate by means of the control buttons 38. If desired, the physician also sets the desired treatment intensity and treatment gap by means of the control buttons 38, and decides whether or not to apply the filter provided by the load 62 and, if so, sets this with a further control key 38.

25

Next, the physician selects an area of the body for treatment and applies the electrical impulses to different body zones within this area. A number of initial

readings will thus be generated and stored in the memory 56, and from the readings on the display location 36a the physician will select a number of zones with relatively high initial readings, representing a relatively high skin impedance, and will apply a treatment dose until the audio indicator 58 rings the bell. A new series of readings displayed at the display location 36b is thus generated and stored in the memory 56. The physician now selects the highest of this second series of readings and applies a further set of electrical impulses until the audio indicator 58 sounds the buzzer. At this moment, a final reading is obtained as shown at the display location 36b corresponding to a zero at the display location 36c, and this final reading is also stored in the memory 56.

In the preferred embodiment of the invention, the physician will in practice follow a precise treatment plan under the guidance of the CPU 42, and the display 36 will be arranged to alternate under the control of the CPU 42 between the display shown in Figure 1 and one of the displays shown respectively in Figures 15 and 16. Such a treatment plan will now be described with reference to Figures 15 and 16 and the flow charts of Figures 17 to 20.

Referring firstly to Figures 15 and 16, these show two treatment maps 60 and 62 respectively. The map 60 represents the treatment of the back of a patient, and the map 62 represents the treatment of the face of a patient. In the preferred embodiment, the display 36 of the treatment device 10 is arranged to alternate between the display shown in Figure 1 and described above and a display showing one of the two maps 60 or 62. This alternation takes place either automatically under the control of the CPU 42 following the production of each new skin impedance reading. Alternatively, it is possible for the display to alternate between the two visual outputs on a timed basis or in response to user activation of a further control button 38. A further possibility is for the treatment device 10 to be connected to a PC during treatment, either

by way of a physical connection line or by way of a wireless connection such as an infrared or bluetooth link, and to display the display of Figure 1 on the device and the maps 60 and 62 on the screen of the PC.

5 In any event, each treatment map 60 and 62 comprises an outline 64 representing the predetermined area of the body being treated, the back in the case of Figure 15 and the face in the case of Figure 16. Within the outline 64 a series of map locations 66 are designated, each representing a different zone of the body area in question. The two maps shown in Figures 15 and 16 represent
10 a completed treatment and therefore each map location contains one or more count values representing the skin impedance of the associated zone of the relevant body area. However, at the start of treatment, each map 60 and 62 will comprise simply the outline 64 and the series of designated positions.

15 The generation of the maps shown in Figures 15 and 16 during a treatment session will now be described with reference to the software steps shown in Figures 17 to 20.

20 It is assumed in the following description that treatment will start with the back of the patient. Treatment commences at step 100 in Figure 17 with switching on the treatment device 10 by means of the on/off switch 34. Treatment of the back then commences with the sub routine represented in step 102 and shown in detail in Figure 18, in which a series of readings are taken successively from the neck down the centre of the back following the line of the spine,
25 represented by the line 68 in Figure 15.

This sub routine 102 commences at step 200 in Figure 18 when the treatment device 10 is placed on skin zone 1 at the top of the spine and a reading is taken. This reading yields the count value 24 from the counter 52 in the CPU 42 and

is displayed as a start dynamic value at the display location 36a on the display 36 in Figure 1. In step 202, the CPU stores the count value 24 in the memory 56 and switches the display 36 to the map 60 shown in Figure 15 and displays the count value 24 at map location 1. The software then prompts the physician in step 204 to move the treatment device 10 to skin zone 2 and take a further reading. Such prompting may, for example, take the form of a light flashing on the display at the map location 2 corresponding to the skin zone 2. The physician takes a further reading and the display 36 reverts to its original display and displays this further initial reading or start dynamic value at the display location 36a in Figure 1. Again, the new start dynamic value is stored in the memory 56 and the map 60 is brought up on the display with the count value 26 now shown in map location 2. This is represented in step 206.

In step 208, the software checks whether the count value at map location 1 is four or more higher than the count value at map location 2. If yes, the physician is prompted to move the treatment device 10 back to skin zone 1 and apply a treatment dose in step 210. A treatment dose is a series of electrical impulses applied until the position X is reached on the graph shown in Figure 14 and until the audio indicator 58 rings the bell. The treatment dose given in step 210 will generate a corresponding count value in display location 36b on the display 36. The CPU 42 stores this dose count value in the memory 56 in step 212 and, reverting to the map 60, displays the dose value against map location 1. The dose value is indicated by a "star" on the map 60. On the other hand, if the answer to the question posed in step 208 is no, the software proceeds to step 214 and checks whether the value at map location 2 is four or more higher than the value at map location 1. If yes, the physician is prompted to maintain the treatment device 10 at skin zone 2 and to apply a treatment dose here in step 216. Once again, this generates a dose count value in the display location 36b in Figure 1, and in step 218 the CPU 42 stores this dose count

value in the memory 56 and, reverting to the treatment map 60, displays the dose count value in map location 2.

5 The software then proceeds from the relevant one of steps 212, 214 and 218 to step 220 in which the CPU 42 registers that the next skin zone to be treated is skin zone N, which is equivalent to skin zone 3. The device prompts the physician to move the treatment device 10 in step 222 to skin zone N, i.e. in this instance skin zone 3, and take a further reading. A new start dynamic count value is generated and in step 224 this is stored in the memory 56 and is
10 displayed on the map 60 at map location N, which is at the third position in this instance. As shown in the specific example of Figure 15, the start dynamic value at map location 3 is 32. In step 226, the software checks whether the start dynamic value at map location N ($N = 3$) is four or more higher than the start dynamic values at the previous map locations. If yes, the physician is
15 prompted to maintain the treatment device 10 at body zone 3 and to apply a treatment dose until the audio indicator 58 rings the bell. This is step 228. When the bell has rung and the dose count value is displayed at display location 36b on the display 36 in Figure 1, the CPU stores the dose count value in the memory 56 and displays the value at map location N ($N = 3$) in step 230.

20

Referring to Figure 15, it will be seen that the specific example illustrated has a start dynamic count value of 32 in map location 3 and that this is the first occasion on which a value sufficiently high to prompt a treatment dose has been reached. The dose count value in this instance is shown to be 47.

25

In the case where the value at location N is not four or more higher than the previous highest start dynamic count value, the treatment process proceeds from step 226 directly to step 232 where the CPU 42 checks whether the final map location has been reached in the spine series. If no, the CPU 42

- increments N by 1 in step 234 and returns to step 222. If yes, the CPU prompts the physician in step 236 to remain at skin zone N and apply a treatment dose. The dose count value is stored in step 238 in the memory 56 and is displayed on the treatment map 60. Referring to Figure 15, the final location N is in fact shown above location 1 and represents the neck of the patient. The start dynamic count value here in this example is 28 and the dose count value is 45. This finishes the series of readings generated in the sub routine of step 102 and the CPU 42 returns to step 104 in Figure 17.
- 10 In step 104, the software reviews the dose count values from the spine series and selects the one that has the highest value. The software prompts the physician in step 106 to move the treatment device to the relevant skin zone and to administer a full treatment. In this step, the physician holds the treatment device 10 at the relevant skin zone and applies electrical impulses
- 15 until the point Y is reached in the graph in Figure 14, i.e. until a value of zero representing dZ/dt is displayed at display location 36c of the display 36 in Figure 1 and the audio indicator 58 sounds the buzzer. The reading at display location 36b at this moment is stored in step 108 in the memory 56 and is displayed on the map 60 at the relevant map location. In the example shown in
- 20 Figure 15, the full treatment is applied at body zone 5, represented by map location 5 on the map 60 and the full treatment value is shown as 120.
- Having now completed a series of treatment applications along the spine of the patient, the treatment moves to the sub routine represented in step 110 and
- 25 shown in Figure 19 and readings are taken down the two paravertebral lines 70 and 72 flanking the spine.

The sub routine 110 commences at step 300, in which the device prompts the physician to place the treatment device 10 on skin zone $N1=1$, which is at the

top of paravertebral line 70. The physician initiates the electrical impulses and a start dynamic count value for this skin zone is generated. In step 302, the software stores the new start dynamic count value in the memory 56 and displays the value at map location N1 corresponding to skin zone N1. In the example shown in Figure 15, the start dynamic count value here is 31. In step 304, the software prompts the physician to move the treatment device 10 across to the same level on the patient's right to position N2, and there another start dynamic count value is generated. This start dynamic count value is stored in the memory 56 and is then displayed at map location N2 of the map 60 in step 306. The software now considers in step 308 whether the start dynamic count value for body zone N1 is four or more higher than that for body zone N2. If yes, the software prompts the physician in step 310 to return to body zone N1 and apply a treatment dose. The dose count value thus generated is stored in the memory 56 and is displayed at map location N1 in step 312. If the answer to step 308 is no, however, the software proceeds to step 314 and enquires whether the start dynamic count value at body zone N2 is four or more higher than that at body zone N1. If yes, the software prompts the physician in step 316 to hold the treatment device 10 at body zone N2 and apply a treatment dose. The dose count value thus generated is stored in the memory 56 displayed at map location N2 in step 318.

Following step 312 or step 318, as appropriate, the software proceeds to step 320 where N1 is incremented by 1 and prompts the physician in step 322 to move to the new body zone $N1 + 1$ and take a reading. The start dynamic count value thus generated is stored in the memory 56 and is displayed at map location $N1 + 1$ in step 324. In step 326, the software enquires whether the value and map location $N1 + 1$ is four or more higher than the highest previous start dynamic count value. If yes, the software prompts the physician in step 328 to remain at body zone $N1 + 1$ and apply a treatment dose. The dose count

value thus generated is stored in the memory 56 and displayed at map location $N1 + 1$ in step 330. The software now proceeds to step 332. On the other hand, if the outcome of the enquiry in step 326 is no, the software proceeds immediately to step 332. Here the software enquires whether the last position of the lines 70 and 72 on the map 60 has been reached. If no, the software proceeds to step 334, and either moves to the corresponding $N2$ position or reverts to the $N1$ position and increments $N1$ by another 1. The software then reverts to step 322. If yes, the software proceeds to step 336 and prompts the physician to remain at the final position and apply a treatment dose. The dose count value thus generated is stored in the memory 56 and displayed on the map 60 at the final position in step 338.

In the example shown in Figure 15, the readings are taken alternately down the paravertebral lines 70 and 72 finishing with the two alternating neck positions with the final position again being at the neck of the patient on the right. This completes the sub routine of step 110.

The software now proceeds to step 112 in which it scans the dose count values from both paravertebral lines 70 and 72 and selects the one which is the highest. In step 114, the software prompts the physician to move the treatment device 10 to the corresponding skin zone and to apply a full treatment until the rate of change of skin impedance with time reaches zero. The treatment count value thus generated is stored in the memory 56 and displayed at the associated map location in step 116.

Referring to the example shown in Figure 15, it will be seen that the highest dose count value for the two paravertebral lines 70 and 72 is at the ninth map location, which is in line 70 and has a value 65. At this map location, the further treatment value 98 obtained in step 116 is also displayed.

The software now proceeds to step 118 and scans the treatment count values in the whole of the map 60 and selects the one with the highest value. In step 120, the software prompts the physician to move the treatment device 10 to the associated body zone and to apply a further treatment, designated an FM treatment, for a period of two minutes. With reference to the example shown in Figure 15, the highest treatment count value is at the fifth position of the spinal series of readings and is 120. The FM treatment in this instance is applied at the body zone corresponding to this map location.

During this frequency modulation treatment, the software in the CPU 42 generates a pulse output for supply to the waveform generator 46, which pulse output cycles through a range of frequencies from 15 Hz to 351 Hz with each successive cycle lasting for a duration of 8 seconds. The primary purpose of this further FM treatment is to access additional communication paths in the network 12 of nerves within the body in order to provide an additional healing stimulus. It is believed that the main treatment, which has been carried out up until this point, sets up a biofeedback loop along a dominant communication path. This generates the main healing stimulus. However, it is possible that there may also be other associated communication paths, which are either accessory to the main process or are linked to previous pathology. These other communication paths may not be addressed by the application of the main treatment through the biofeedback loop but may instead respond to electrical impulses applied at different frequencies. Thus, these other communication paths may be reached by cycling through the frequency range of the activation pulses, and it is for this reason that the final FM treatment is applied.

In step 122, the count value displayed at display location 36b on the display 36 in Figure 1 at the culmination of the FM treatment is stored in the memory 56 and is displayed at the associated map location in step 122.

5 The software now proceeds to the sub routine represented in step 124 and shown in Figure 20. This sub routine relates to the treatment of a patient's face and is represented by the map 62 shown in Figure 16.

10 The sub routine 124 starts at step 400 in which the software sets the value N representing the relevant body zone on the patient's face to the value 1. In step 402, the software prompts the physician to move the treatment device 10 to the position N, i.e. initially the first position, and begin treatment. The start dynamic count value thus generated is stored in the memory 56 and is displayed at the corresponding map location on the facial map 62. In the
15 example shown in Figure 16, the first position is at the bottom right hand of the face and the corresponding start dynamic count value is 31.

The software proceeds to step 404 and prompts the physician to move the treatment device 10 to position 2, which is the lower left hand position of the
20 face, and to begin treatment. The start dynamic count value for this body zone is stored in the memory 56 and is displayed on the facial map 62 at the map location 2, being the count value 36 in the example of Figure 16. This is step 406. The software now proceeds to step 408 and enquires whether the count value for facial zone 1 is one or more higher than the count value for facial
25 zone 2. If yes, the software prompts the physician to return to facial zone 1 and apply a treatment dose in step 410. The dose count value thus generated is stored in the memory 56 and displayed at map location 1 in step 412.

On the other hand, if the response to the enquiry of step 408 was no, the software proceeds to step 414 and enquires whether the start dynamic count value is one or more higher at facial zone 2 than at facial zone 1. If yes, the software prompts the physician in step 416 to remain at facial zone 2 and apply a treatment dose. The dose count value thus generated is stored in the memory 56 and displayed at map location 2 in step 418. In the example shown in Figure 16, the start dynamic count value at map location 2 is 36 which fulfils the enquiry at step 414, and a corresponding dose count value of 51 is displayed. The software then proceeds from step 418 to step 420. If the enquiry at step 414 yields the answer no, the software also proceeds to step 420 in which the value N is incremented by 1.

Next, in step 422, the software prompts the physician to move the treatment device 10 to facial zone 3, which is at the centre right of the face, and to begin treatment. A new start dynamic count value is generated and in step 424 this is stored in the memory 56 and is displayed at the corresponding map location of the facial map 62. In step 426, the software enquires whether the start dynamic count value at the third map location, which represents the third facial zone, is one or more higher than the highest previous start dynamic count value for the face. If yes, the software proceeds to step 428 and prompts the physician to apply a treatment dose at this zone. In step 430, the dose count value thus generated is stored in the memory 56 and is displayed on the facial map 62 at the third map location. The software now proceeds to step 432. On the other hand, if the response to the enquiry at step 426 is no, the software proceeds directly to step 432 and enquires whether the last facial zone has been reached. If no, the software increments the value N by 1 in step 434 and reverts to step 422. If yes, the software proceeds to step 436 and applies a treatment dose at the last facial zone. The dose count value thus generated is stored in the memory 56 and displayed at the corresponding map location in step 438.

With reference to Figure 16, the last facial zone is the one at the top left hand side of the face where, in the example given, the start dynamic count value is displayed as 38 and the dose count value is displayed as 53. This completes the sub routine of step 124 and the software now proceeds to step 126. Here, the software scans the dose count values for the facial zones stored in the memory 56 and selects the one with the highest value. The software then prompts the physician in step 128 to move the treatment device 10 to the corresponding facial zone and apply a full treatment. The count value generated at the moment when dZ/dt becomes zero is stored in the memory 56 and is displayed on the facial map 62 in step 130. Referring to the facial map 62 in Figure 16, the highest dose count value is seen to be at the top right hand side of the face, being 58, and the full treatment is applied at the corresponding facial zone and yields a full treatment count value 87.

The software now proceeds to step 132 and scanning the values in the memory 56 enquires whether the full treatment count value for the face is higher than the full treatment count values for the back. If no, the treatment is finished. If yes, the software proceeds to step 134 and prompts the physician to remain at this facial zone and apply an FM treatment for a duration of two minutes. This FM treatment yields a further count value, which in step 136 is stored in the memory 56 and displayed at the corresponding map location.

The treatment is now finished.

The above description of a treatment session with the aid of the treatment maps 60 and 62 shown respectively in Figures 15 and 16 and the flowcharts shown in Figures 17 to 20 assumes that the software in the CPU 42 is designed to undertake all the processing to evaluate which body zones should receive

treatment doses and which body zones should receive full treatment and is designed also to prompt the physician to move in each case to the relevant body zone. It is, of course, also possible to employ a simplified form of the software, in which the software simply reads the treatment values and stores the relevant readings in the memory 56 and displays them on the treatment maps. In this case, the physician firstly selects each new position for the treatment device 10 by inspection of the treatment map, and secondly selects the relevant body zones for receiving treatment doses and full treatment by inspection of the treatment map.

10

In a further application of the present invention, the treatment device 10 may be employed as part of a treatment system in which the results of each treatment session may be transferred from the treatment device 10 to a practitioner's PC and thence to a server database for holding full details of a patient's history.

15

Easy access to the server database may be controlled by means of a smart card for accessing the patient's details for each new treatment session, whether they are visiting their original practitioner or a different one. This treatment system is shown in Figures 21 to 24.

20

Referring to Figure 21, the treatment system comprises the treatment device 10 with its CPU 42, and a cradle 80 for receiving the treatment device 10. The cradle 80 is connected to a practitioner's PC 82, for example by way of a USB link 84, for communicating information between the treatment device 10 and the PC 82. The cradle 80 may also contain a charger (not shown) for charging the battery 40 in the treatment device 10. The practitioner's PC 82 has access to a server database 86 by way of the Internet 88 or other communication mode. By these means, the results of each treatment session stored in the memory 56 of the treatment device 10 may be downloaded to the practitioner's PC 82 and thence to the server database 86. Correspondingly, the results of

25

any previous treatment sessions may be accessed by the practitioner through the PC 82, and relevant information may be downloaded to the treatment device 10 for reference in a new treatment session.

- 5 In order to control access to such information, and hence to ensure that confidentiality is maintained and that a patient's record can only be accessed in association with the patient, the patient may carry a smart card 90 bearing a security PIN. The cradle 80 is designed to receive the smart card 90, and the CPU 42 in the treatment device 10 is designed to be able to read the smart card
- 10 90 for accessing the relevant records on the server database 86 by way of the PC 82. The events, which take place during the first and subsequent treatment sessions in this respect, are shown in Figures 22 and 23, and the software in the CPU 42 and corresponding steps are shown in Figure 24.
- 15 Referring initially to Figure 22, in the first treatment session, the patient fills in a registration form for the practitioner. The practitioner enters the data from the registration form into the PC 82 as the patient record as event 1 in Figure 22. The treatment device 10 accesses the patient record as event 2 and using the information in the patient record applies a unique patient ID to a blank card
- 20 90 inserted in the cradle 80 to create a new smart card. This is event 3 in Figure 22. Subsequently, the practitioner administers a treatment session, the results of which are recorded in the memory 56 of the CPU 42 as previously described. After the treatment session, as event 4 in Figure 22, the treatment device 10 is returned to the cradle 80, and then the results of the treatment
- 25 session are transferred from the treatment device 10 to the PC 82 as event 5. Subsequently, both the patient record on the PC 82 and the results of the treatment session are transferred from PC 82 to the server database 86 as event 6. The patient takes the smart card 90 and departs.

In a subsequent treatment session, represented in Figure 23, the session commences with the patient inserting the imprinted smart card 90 into the cradle 80 as event 1. The CPU 42 of the treatment device 10 reads the unique patient ID from the smart card 90 as event 2 in Figure 23, and transfers the patient ID to the PC 82 as event 3. As event 4, the PC 82 supplies the patient ID to the server database 86 and then during event 5 retrieves the patient records from the server database 86. The treatment device 10 then retrieves any relevant information from the PC 82 as event 6 for use during the treatment session. The treatment device 10 records the results of the treatment session, following which the practitioner replaces the treatment device 10 in the cradle 80 as event 7. The results of the treatment session are now transferred as event 8 from the treatment device 10 to the PC 82. Finally, as event 9, the full patient record with the results of the treatment session are transferred from the PC 82 to the server database 86, and the patient retrieves the smart card 90 from the cradle 80.

The processing steps, which take place within the CPU 42 of the treatment device 10 during these events, are shown in Figure 24 and will now be described.

20

At the start of a treatment session, whether this is the first or a subsequent treatment session, the practitioner places the treatment device 10 in the cradle 80 in step 500. The software of the CPU 42 interrogates the cradle 80 to discover whether a smart card is detected. This is step 502. If no, the software proceeds to step 504 and prompts the practitioner to request the patient to enter a smart card. The software then reverts to step 502. On the other hand, if a smart card is detected, the software proceeds to step 506 and interrogates the smart card 90 to establish whether it carries a unique patient ID. If no, the software proceeds to step 508 and prompts the PC 82 to create a new or select

an existing patient record. The treatment device 10 then requests the PC 82 to download the patient ID to the treatment device 10 by way of the cradle 80 in step 510. The software reads the patient ID and stores this ID on the smart card 90 in step 512 and then proceeds to step 514 and requests the patient to enter a new PIN number by way of a keypad (not shown) on the cradle 80. The software stores this PIN number on the smart card as part of the patient ID.

The software then reverts to step 506 and enquires whether a smart card 90 is detected in the cradle 80. If yes, the software proceeds to step 516 and the treatment device 10 reads the patient ID from the smart card, and then prompts the patient in step 518 to enter their PIN number via the keypad on the cradle 80. The software allows the patient a given number, say three, attempts at this. The software verifies the PIN number that has been input against the unique patient ID on the smart card in step 520. If the two match, the treatment device 10 requests the patient history from the PC 82 in step 522. The PC 82 retrieves the patient history from the server database 86 and supplies the relevant information to the treatment device 10. On the other hand, if the PIN number and the patient ID do not match after a number of attempts, the software terminates the treatment in step 524 and issues an alert to the PC 82.

Once the treatment device 10 has the necessary information, the practitioner removes the device from the cradle 80 and performs a treatment session, during which the treatment results are stored in the memory 56 of the device in step 526. After the treatment session, the practitioner replaces the treatment device 10 in the cradle 80, at which point in step 528 the software detects the presence of the cradle 80 and proceeds to step 530. In step 530, the treatment device 10 enquires whether the PC 82 is ready to receive a new treatment record. If yes, the treatment device 10 downloads the results of the treatment session to the PC 82 by way of the cradle 80 in step 532. Then, in step 534 the treatment device 10 requests the PC to transmit the treatment record to the server

database 86. On the other hand, if the results of the enquiry of step 530 are no, for any reason, the treatment device 10 retains the treatment results in its memory 56 and terminates the treatment session in step 536.

5 In the described embodiment, most of the processing is conducted within the CPU 42 of the handheld device 10. However, it will be appreciated that various modifications are possible within the scope of the invention. For example, some of the processing can be shared with the CPU in the practitioner's PC 82 as also can some of the display features.

10

Other modifications are also possible. For example, the comparator 50 for detecting feedback signals from the electrodes 32 may be replaced by alternative detection means. Instead of measuring the duration of the pulses output by the comparator for detecting the time between crossings of the feedback waveform, detection means for measuring the peak value of the feedback waveform or the area between the feedback waveform and a threshold line may be employed.

15

Other possible variants include the replacement of the audio indicator 58 with a visual indicator and the replacement of the control buttons 38 with different control input means. The audio indicator may also be provided with a facility for issuing entertaining sounds, such as animal noises, for use when children are being treated for keeping their interest alive.

20

25 The treatment device and method of the present invention have numerous significant advantages.

In particular, it has been found that the treatment device of the present invention as described above is capable of effectively treating a wide variety of

illness and disease, as well as other clinical conditions. The device also has the advantages of being portable and easy to use and relatively inexpensive to manufacture and produce.

- 5 Further the provision of patient records for future referral is of significant benefit in monitoring the progress and outcome of treatment.

CLAIMS

1. A treatment device for applying electrical impulses to a living body through the skin, for treating a variety of clinical conditions, comprising:

5 A pair of electrodes for contact with the skin;

A waveform generator for repeatedly generating an AC waveform for applying electrical impulses through the electrodes to the skin;

A detector for detecting changes in the skin impedance and for generating output signals representing the skin impedance;

10 Means responsive to the output signals from the detector for monitoring the responsivity of the skin; and

Indicator means for generating a first indication when a predetermined level of responsivity is reached and a second indication when a pre-determined treatment has been administered.

15

2. A treatment device according to claim 1, in which:

The detection means generates output signals in the form of pulses whose duration represents the skin impedance;

The monitoring means measures the duration t of each pulse; and

20 The indicating means is arranged to generate each indication when t satisfies a predetermined function of t .

3. A treatment device according to claim 2, in which:

The indicating means is arranged to generate the first indication when:

25 $t_2 = 4.087 t_1^{0.7131}$

4. A treatment device according to claim 2 or 3, in which:

The indicating means is arranged to generate the second indication when:

$$dZ/dt = 0$$

where Z is the skin impedance.

5

5. A treatment device according to any preceding claim, in which the AC waveform is a decaying sinusoidal waveform having an initial amplitude V_{peak} , a half wavelength t_1 and a decay t_{decay} and in which V_{peak} , t_1 and t_{decay} can all be variably set by the user.

10

6. A treatment device according to claim 5 in which the repetition rate of the repeatedly generated AC waveform can be variably set by the user.

15

7. A treatment device according to any of claims 1 to 6 in which the detector comprises a comparator for comparing an output from the electrodes with a threshold level and for generating output pulses whose duration is determined by the threshold level.

20

8. A treatment device according to claim 7 in which the duration of the output pulses represents the skin impedance.

25

9. A treatment device according to claim 7 or 8 in which the monitoring means comprise means for measuring the duration of the pulses output by the comparator.

10. A treatment device according to any preceding claim, in which the indicator means comprise at least one audio indicator.

11. A treatment device according to any preceding claim, which is battery powered.

12. Treatment apparatus for applying electrical impulses to a living body through the skin, for treating a variety of clinical conditions, comprising:

A pair of electrodes for contact with the skin;

A waveform generator for repeatedly generating an AC waveform for applying electrical impulses through the electrodes to the skin;

Means responsive to a resistance generated between the electrodes due to the skin impedance for detecting the responsivity of different zones of a predetermined area of the body and for producing output data representing the responsivity of each zone;

A store for the output data; and

Means for selecting a treatment zone from amongst the different zones based on an evaluation of the output data to select the zone of greatest responsivity.

13. Treatment apparatus according to claim 12, in which the output data is in the form of numerical values, and the selecting means evaluates the data according to the highest value.

14. Treatment apparatus according to claim 12 or 13, in which the selecting means comprise means for processing the output data contained in the store, and a display operable by the processing means for indicating the selected treatment zone.

15. Treatment apparatus according to claim 14, in which the processing means is arranged to present on the display a body map having an outline representing the predetermined area of the body and a plurality of map

locations within the outline, each of which represents a corresponding zone of the predetermined area.

5 16. Treatment apparatus according to any of claims 12 to 15, in which the processing means are arranged to present at each map location on the display output data representing the associated zone.

10 17. Treatment apparatus according to any of claims 12 to 16 including a treatment device according to any of claims 1 to 11.

15 18. A treatment system for the treatment of a living body, comprising:
a treatment device for applying electrical impulses to the body through the skin, the treatment device including a CPU;
a PC for storing patient records;
15 a cradle for the treatment device, the cradle being connected to or incorporated as a part of the PC; and
means for receiving a smart card including a unique patient ID and for providing access to the patient records associated with the unique patient ID.

20 19. A treatment system according to claim 18 in which the cradle includes a receptacle for the smart card.

25 20. A treatment system according to claim 18 or 19, in which the smart card carries a PIN number, and further comprising input means by which a patient can input their PIN number, and means for verifying that the input PIN number matches the patient ID on the smart card.

21. A method of treating a living body through the skin, comprising the steps of:

placing a pair of electrodes in contact with the skin;

generating an AC waveform to supply electrical impulses through the electrodes to the skin;

5 detecting changes in the skin impedance and generating output signals representing the skin impedance;

monitoring the responsivity of the skin; and

indicating firstly when a predetermined level of responsivity is reached and secondly when a predetermined treatment has been administered.




FIGURE 1

FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5






FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11

Analogue Waveform




FIGURE 12

Amplitude
of
Gwei






Figure 13



See ring 11er:
 $t^2 = 4.07t$
0.7131



Speed 'O' 11er t is unchanged
as decreasing for > 15cc.

Skin Impedance vs. Time





FIGURE 14

FIGURE 16

3 paths technique



70	35	28/45*	34/55*
31	68	C7	72
34	24	34/51*	
38/60*	26	27	
39	35	34	
42/65*	39/59*	39	
39	42	41	
32	28	29	
34	24	28	
33	26	28	

FIGURE 15

60




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22

Data Flow - Subsequent Patient Visits




FIGURE 23




FIGURE 24

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.